Category Archives: Uncategorized

Challenge to recent Fourth Circuit decision on false advertising to consumers

Last month, the Fourth Circuit held in In re GNC Corp. that "to state a false advertising claim on a theory that representations have been proven to be false, plaintiffs must allege that all reasonable experts in the field agree that the representations are false.” — F.3d –, 2015 WL 3798174, at *7 (4th Cir. […]

Watch CSPI’s video about Coke and diabesity

The Center for Science in the Public Interest has remade Coke's famed “Hilltop” ad to drive home the relationship between sugary soft drink consumption and obesity (and obesity's cousin, diabetes). CSPI recently reported that its video has been view more than 300,000 times in English. To view the video in English, go here or click on […]

The CFPB’s guides to money management

The Consumer Financial Protection Bureau has published consumer guides for managing money particularly aimed at helping newcomers to the U.S. Here's what the CFPB says about the guides, along with links to the guides themselves: Beneficiary. Collateral. Debit. Fair market value. These terms might look familiar, but what do they really mean? Now imagine how […]

Class Actions and the Counterrevolution Against Federal Litigation

That's the name of this article by law professor Stephen Burbank and political scientist Sean Farhang. Its part of a larger study about the counterrevolution against private enforcement of legal rights. Here is the abstract: In this article we situate consideration of class actions in a framework, and fortify it with data, that we have […]

ProPublica study finds blood thinning drug widely used, insufficiently monitored

Today's Washington Post reports on a ProPublica expose concerning the use of the drug Coumadin, a popular (in the sense of widely used) anti-coagulant used by many elderly people to prevent blood clotting. (The Post headline jumped out at me in part because two of my own relatives use or have used the drug in […]

Fish Oil, Snake Oil, the FDA and the Courts

Brian Wolfman blogged yesterday about a Washington Post story pointing out that fish oil supplements are being marketed to consumers to lower the risk of heart disease despite the absence of scientific evidence bearing out their effectiveness. The FDA allows manufacturers of the supplements to get away with making a "qualified health claim" that "supportive […]